Canagliflozin hemihydrate is a highly potent and selective inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. It is an experimental drug being developed by Johnson & Johnson for the treatment of type 2 diabetes.
Products > Life Science > Carbohydrates, Nucleosides & Nucleotides > Carbohydrates > Glycosides | Products > Drug Discovery > Inhibitor
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye